

TAKARA BIO

Newer technologies assisting the sustainable disease modelling

Presenter:

Karthi Rajamani*

Presentation abstract:

Drug development is often an expensive and time consuming process. Usage of sub-optimal preclinical models hinders the regulatory approval for many drugs. Animal models are becoming increasingly unreliable because they do not accurately represent the human body and are neither ethical nor sustainable. Currently, there is also a need for patient-specific models that can accurately replicate the physiological state of diseased tissue. Consequently, newer technologies such as organoids and spheroids are gradually replacing animal models. Also in the therapeutic space, there is a lot of traction in relation to upscaling expansion and differentiation using bioreactors. In this talk, I would like to share our contributions in the organoid and spheroid space, by sharing two interesting studies using Takara Bio solutions.



**Karthi Rajamani is a market strategy manager for Drug Discovery at Takara Bio Europe. She is a neurobiologist by training with a Ph.D. and postdoctoral research experience working with stem cells and animal models. She manages Takara Bio Europe's stem cell portfolio as a market strategy manager, with an interest in communicating and collaborating with scientists on new technologies such as organoids and organ on a chip for drug discovery.*